For patients with CKD without T2DM, the recommendation is to initiate treatment with SGLT2 inhibitors in addition to maximum tolerated renin-angiotensin-aldosterone system (RAAS) blockade in patients with very high KDIGO risk and an eGFR >20ml/min/1.73m2 [15]. The gene discussed is SLC5A2; the disease is chronic kidney disease.